Recombinant Human Thrombopoietin

Generic Name
Recombinant Human Thrombopoietin
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
E2E529W34D
Background

Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells and is used to promote the generation of megakaryocytes and platelets. This drug is used in the treatment of thrombocytopenia.

Indication

用于治疗实体肿瘤化疗后所致的血小板减少症，使用对象为血小板低于50×109/L且医生认为有必要升高血小板数目。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia

Phase 2
Recruiting
Conditions
Sepsis
Thrombocytopenia
Interventions
Drug: Placebo
Drug: rhTPO
First Posted Date
2016-03-14
Last Posted Date
2024-04-18
Lead Sponsor
Ruilan Wang
Target Recruit Count
200
Registration Number
NCT02707497
Locations
🇨🇳

Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, Shanghai, China

Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients

Not Applicable
Conditions
Multiple Myeloma
Interventions
Drug: rhTPO
Drug: CTX
Drug: -CSF
First Posted Date
2015-10-09
Last Posted Date
2017-02-09
Lead Sponsor
Wang Guorong
Target Recruit Count
200
Registration Number
NCT02572596
Locations
🇨🇳

Beijing Chaoyang Hospital, Beijing, Beijing, China

Prospective Study of Patients With Thrombocytopenia Following HSCT

First Posted Date
2015-07-01
Last Posted Date
2020-05-06
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
97
Registration Number
NCT02487563
Locations
🇨🇳

The First affiliated Hospital of SooChow University, Suzhou, Jiangsu, China

A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy

Phase 3
Completed
Conditions
Immune Thrombocytopenia
Pregnancy
Interventions
Drug: rhTPO
First Posted Date
2015-03-18
Last Posted Date
2020-03-20
Lead Sponsor
Shandong University
Target Recruit Count
31
Registration Number
NCT02391272
Locations
🇨🇳

Qilu Hospital, Shandong University, Jinan, Shandong, China

Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy

Phase 3
Conditions
Immune Thrombocytopenia
Pregnancy
Interventions
Drug: rhTPO
First Posted Date
2014-10-21
Last Posted Date
2016-04-20
Lead Sponsor
Shandong University
Target Recruit Count
30
Registration Number
NCT02270801
Locations
🇨🇳

Shandong University Qilu hospital, Jinan, Shandong, China

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Phase 4
Completed
Conditions
Thrombocytopenia
Interventions
Drug: recombinant human thrombopoietin
First Posted Date
2014-10-20
Last Posted Date
2020-03-20
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
58
Registration Number
NCT02267993
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia

First Posted Date
2014-09-19
Last Posted Date
2016-04-20
Lead Sponsor
Shandong University
Target Recruit Count
80
Registration Number
NCT02244658
Locations
🇨🇳

Qilu hospital, Shandong University, Jinan, Shandong, China

A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Phase 3
Withdrawn
Conditions
Immune Thrombocytopenia
Interventions
Drug: Cyclosporin A
Drug: rhTPO
First Posted Date
2014-07-29
Last Posted Date
2016-04-20
Lead Sponsor
Shandong University
Registration Number
NCT02203422
Locations
🇨🇳

Qilu Hospital, Shandong University, Jinan, Shandong, China

Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP

First Posted Date
2013-03-06
Last Posted Date
2013-03-06
Lead Sponsor
Peking Union Medical College
Target Recruit Count
120
Registration Number
NCT01805648
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

First Posted Date
2011-03-22
Last Posted Date
2017-03-03
Lead Sponsor
Chinese Society of Lung Cancer
Target Recruit Count
11
Registration Number
NCT01319669
Locations
🇨🇳

Guangdong General Hospital, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy